Clinicopathological Evaluation of Preoperative Chemotherapy with Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel for Locally Advanced Breast Cancer

By Miyake Tomohiro   Miyahara Shigeki   Fujii Koji   Masanori   Tanimura Manabu   Yamamura Kentarou   Tadokoro Kyoko   Nakamura Haruyo  

Japanese Journal of Cancer and Chemotherapy, Vol. 36, Iss. 3, 2009-03 ,pp. : 401-405

Sunmedia

Access to resources Recommend Favorite

Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control

By Albert Jeffrey  

Breast Cancer Research and Treatment, Vol. 128, Iss. 2, 2011-07 ,pp. : 421-427

Springer Publishing Company

Access to resources Recommend Favorite

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial

By Hadad Sirwan  

Breast Cancer Research and Treatment, Vol. 128, Iss. 3, 2011-08 ,pp. : 783-794

Springer Publishing Company

Access to resources Recommend Favorite

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 3, 2004-09 ,pp. : 211-213

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer

By                

Oncology Letters, Vol. 4, Iss. 4, 2012-01 ,pp. : 612-616

Spandidos Publications

Access to resources Recommend Favorite